Bristol Myers Squibb Stock Is Likely To Offer Better Returns Over This Life Sciences Company

Forbes

We think that Bristol Myers Squibb stock (NYSE: BMY) currently is a better pick compared to its industry peer Bio-Rad Laboratories stock (NYSE: BIO), a life sciences company, given its better growth prospects and comparatively lower valuation of 3.3x trailing revenues, compared to 5.7x for Bio-Rad..